BRPI0516942A - método e composição para reduzir o peso corporal em um mamìfero - Google Patents

método e composição para reduzir o peso corporal em um mamìfero

Info

Publication number
BRPI0516942A
BRPI0516942A BRPI0516942-9A BRPI0516942A BRPI0516942A BR PI0516942 A BRPI0516942 A BR PI0516942A BR PI0516942 A BRPI0516942 A BR PI0516942A BR PI0516942 A BRPI0516942 A BR PI0516942A
Authority
BR
Brazil
Prior art keywords
body weight
mammal
fatty acid
composition
estrogen
Prior art date
Application number
BRPI0516942-9A
Other languages
English (en)
Inventor
Maria Alemany
Original Assignee
Oleoyl Estrone Developments Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oleoyl Estrone Developments Sl filed Critical Oleoyl Estrone Developments Sl
Publication of BRPI0516942A publication Critical patent/BRPI0516942A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODO E COMPOSIçãO PARA REDUZIR O PESO CORPORAL EM UM MAMìFERO. A invenção refere-se a composições e métodos para reduzir o peso corporal de um mamífero. A presente invenção é voltada para métodos para reduzir o peso corporal em um mamífero que compreende a administração de quantidades terapeuticamente eficazes de um éster de ácido graxo de um estrogênio ou de um derivado de estrogênio e um ácido graxo, e um composto termogênico. Além disso, a presente invenção é voltada para composições que compreendem um éster de ácido graxo de um estrogênio ou de um derivado de estrogênio e um ácido graxo, e um composto termogênico.
BRPI0516942-9A 2004-10-18 2005-10-17 método e composição para reduzir o peso corporal em um mamìfero BRPI0516942A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/969,249 US20060084637A1 (en) 2004-10-18 2004-10-18 Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
PCT/EP2005/011155 WO2006042733A2 (en) 2004-10-18 2005-10-17 Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same

Publications (1)

Publication Number Publication Date
BRPI0516942A true BRPI0516942A (pt) 2008-09-23

Family

ID=36087651

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516942-9A BRPI0516942A (pt) 2004-10-18 2005-10-17 método e composição para reduzir o peso corporal em um mamìfero

Country Status (9)

Country Link
US (2) US20060084637A1 (pt)
EP (1) EP1812111A2 (pt)
JP (1) JP2008516920A (pt)
KR (1) KR20070084319A (pt)
CN (1) CN101080250A (pt)
BR (1) BRPI0516942A (pt)
CA (1) CA2584385A1 (pt)
MX (1) MX2007004574A (pt)
WO (1) WO2006042733A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147373A2 (en) * 2006-06-26 2008-12-04 Manhattan Pharmaceuticals, Inc. Methods and compositions for reducing body weight using an estrogen fatty ester in an oil
ES2302449B1 (es) * 2006-10-30 2009-06-12 Oleoyl-Estrone Developments, S.L. Monoesteres de estrogenos con acido linoleico conjugado y usos de los mismos.
US20110098358A1 (en) * 2008-06-11 2011-04-28 Ricom Corporation Human beta3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
JP6479818B2 (ja) * 2013-05-10 2019-03-06 シーエヌアイシー ファンデーション セントロ ナショナル デ インベスティゲイショネス カーディオバスキュレアス カルロス ザ サード 骨髄増殖性新生物の治療に適した化合物
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
CN107029237B (zh) * 2016-02-04 2021-06-25 康建胜 产热增强化合物增强去甲肾上腺素类化合物诱导褐色脂肪细胞产热的应用
CA3203170A1 (en) * 2020-12-24 2022-06-30 Kuen Yong Lee Fatty acid- modified polymer nanoparticles, and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442113A (en) * 1981-05-07 1984-04-10 A/S Ferrosan Long-term weight reduction of obese patients using femoxetine
ES2094687B1 (es) * 1994-08-02 1997-12-16 S A L V A T Lab Sa Combinacion farmaceutica contra la obesidad o el sobrepeso.
PT771817E (pt) * 1995-10-30 2003-06-30 Oleoyl Estrone Developments S Mono-esteres de oleato de estrogenos para o tratamento da obesidade e/ou excesso de peso
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
BR0114836A (pt) * 2000-10-20 2003-07-01 Pfizer Prod Inc Agonistas de receptores beta-3 adrenérgicos e suas aplicações
JP2003013329A (ja) * 2001-06-26 2003-01-15 Sanai Fujita 動物骨製繊維及びその製造方法
US6821961B2 (en) * 2001-08-24 2004-11-23 Michael P. Girouard Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents
EP1545484A4 (en) * 2002-10-05 2010-01-13 Hanmi Pharm Ind Co Ltd PHARMACEUTICAL COMPOSITION COMPRISING CRYSTALLINE SIBUTRAMINE METHANESULFONATE HEMIHYDRATE
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
EP1579872B8 (en) * 2002-12-27 2012-11-07 Takeda Pharmaceutical Company Limited Body weight gain inhibitor

Also Published As

Publication number Publication date
US20060084637A1 (en) 2006-04-20
KR20070084319A (ko) 2007-08-24
WO2006042733A2 (en) 2006-04-27
EP1812111A2 (en) 2007-08-01
JP2008516920A (ja) 2008-05-22
CN101080250A (zh) 2007-11-28
CA2584385A1 (en) 2006-04-27
MX2007004574A (es) 2007-08-14
US20070049569A1 (en) 2007-03-01
WO2006042733A3 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
BRPI0516942A (pt) método e composição para reduzir o peso corporal em um mamìfero
BRPI0813140C1 (pt) método para a preparação de ácido desoxicólico (dca) ou um éster desse ou um sal farmaceuticamente aceitável desse e composto intermediário
BRPI0508936A (pt) composições e métodos para redução ou prevenção de obesidade
CL2011001924A1 (es) Compuestos derivados de aminotetralina, inhibidores de glyt1; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso en el tratamiento de problemas neurologicos, psiquiatricos o dolor.
CR20140392A (es) Dihidropirazolonas sustituidas
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
BR112012024017A2 (pt) compostos derivados de triazina dissubstituída farmaceuticamemnte ativios, composição farmacêutica, método para a síntese destes e uso dos mesmos
SV2008003037A (es) Derivados de amina
MX337408B (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
WO2012068357A3 (en) Cosmetic compositions and methods for inhibiting or reducing trypsin activity based on cyclohexane- 1, 2, 3, 4, 5, 6 -hexol and a n-acyl amino acid compound
BRPI0916456B8 (pt) compostos lipídicos, composições de suplemento alimentar, farmacêuticas e lipídicas, método para produção de compostos lipídicos e uso de compostos lipídicos
HK1080689A1 (en) Compositions comprising short and long chain fattyacids and methods of their use for the management of body weight
BR112012015725A2 (pt) composição antitranspirante/desodorante aquosa
BR112012022634A2 (pt) síntese de derivados de alto-tocoferolquinona e métodos de utilização dos mesmos
BRPI0512514A (pt) composto, antagonista para receptores de crf, e, uso de um composto
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
AR060196A1 (es) Agentes, composiciones y metodos para el aclaramiento de la piel
BR112015001313A2 (pt) composições de vacina
BRPI0518448A2 (pt) composiÇÕes farmacÊuticas compreendendo um derivado de camptotecina
AR086444A1 (es) Composiciones farmaceuticas y metodos para tratar el cancer
MX2009003794A (es) Composicion de prostaglandina e estabilizada.
BR112012017106A2 (pt) combinação, kit e método de redução de pressão intraocular.
BR112013027486A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
RU2012129932A (ru) Средство для предотвращения или ослабления пигментации
BRPI0607795A2 (pt) compostos antiinflamatórios

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/05 (2006.01), A61P 1/14 (2006.01), A61K 31